Jan. 12 at 9:57 PM
$HURA TuHURA’s leadership is grounded in clinical development, immunology, and regulatory execution.
The management and scientific teams bring experience advancing oncology programs from early development through late-stage trials. Led by James Bianco, M.D., President and Chief Executive Officer, with decades of experience advancing oncology programs through late-stage development and regulatory review.
The Board is chaired by James S. Manuso, Ph.D., MBA, bringing deep expertise in biotech leadership and corporate governance.
Medical oversight is strengthened by directors including Alan F. List, M.D., and Craig L. Tendler, M.D., former senior oncology executive at Johnson & Johnson with experience across multiple FDA approvals.
This leadership structure reflects a focus on clinical rigor, regulatory discipline, and execution at scale, with programs advanced through clearly defined clinical endpoints and measurable milestones.
